None listed
Conditions
Interventions
Drug : Oral administraion of Wolbigachul-tang or Socheongryong-tang for 2 weeks, 3 times a day before or between meals
Sponsors
Daejeon Korean Medicine Hospital of Daejeon University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Chronic cough patients for more than 8 weeks, aged 19–75 years 2. Experienced sensation of ‘mucus in the throat' including conditions as rhinorrhea, throat discomfort, itching, foreign body sensation or observed pebble-like changes in posterior pharyngeal wall or has findings indicating sinusitis on PNS X-ray 3. Daytime Cough Symptom Score = 2 points, Night-time Cough Symptom Score = 1 point 4. Patients who consent to participate
Exclusion criteria
Exclusion criteria: 1. Those with abnormal findings that could cause cough as a result of chest x-ray 2. Those with abnormal findings in lung function tests (FEV <80% predicted or FEV1/FVC <70%) 3. Those who have been diagnosed with acute respiratory disease including upper respiratory tract within the last 1 month 4. Those who have been diagnosed with chronic respiratory diseases (chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, interstitial pulmonary disease and other chronic respiratory diseases) within the last 2 years 5. Those who have been diagnosed gastroesophageal reflux disease within the last 1 year 6. Those who have been taking steroids, anti-leukotrienes, anticholinergics, long-acting ß2 agonists, antihistamines, antitussive, and expectorant within the last 2 weeks 7. Those who have taken proton pump inhibitors, histamine receptor antagonists, mucosal protective agents, gastrointestinal motility promoters, antacids, antidepressants, anxiolytics, and lower esophageal sphincter agonists for the treatment of gastroesophageal reflux disease symptoms within the last 2 weeks 8. Those who have been taking or have taken an angiotensin-converting-enzyme inhibitor within the last 4 months 9. Liver or renal impairment (alanine aminotransferase(ALT), aspartate aminotransferase(AST), alkaline phosphatase(ALP), creatinine = 2 times the normal upper limit, at screening) 10. Genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 11. Comorbidities that may interrupt the treatment of cancers or clinical significant disorders of the kidney, liver, psychiatric system, cardiovascular system, respiratory system, endocrine system, and central nervous system, the safety assessment, or completion of this clinical study 12. Unregulated hypertension (systolic blood pressure = 160 mmHg or diastolic blood pressure =100 mmHg in the relaxation period) 13. Unregulated diabetes (fasting blood glucose = 180 mg/dL) 14. Allergy or sensitizer to test drug / comparator 15. History of alcoholism or substance abuse 16. Current smoker or history or smokr more than 30 years 17. Pregnant or breast-feeding 18. Those who did not consent to contraception during the clinical trial 19. Participation in other clinical drug(medicine) trials during the last 30 days before study inclusion 20. Judged by the investigators to be inappropriate for the clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough Symptom Score (CSS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Cough VAS;Nasal Discharge Score;Questionnaire of Clinical Symptoms of Cough and Sputum;Leicester Cough Questionnaire - Korean Verstion (LCQ-K) ;Integrative Medicine Outcome Scale (IMOS);Integrative Medicine Patient Satisfaction Scale (IMPSS);5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L) | — |
Countries
Korea, Republic of
Contacts
Public ContactYee Ran Lyu
Korea Institute of Oriental Medicine
Outcome results
None listed